Article

Candidate methylation sites associated with endocrine therapy resistance in the TCGA ER+/HER2- breast cancer cohort

2019-11-04

Abstract excerpt

<h4>Background</h4> Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, about 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation profile have been implicated as one of the mechanisms through which therapy resistance develo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1f0d2bf6-08ae-5c3d-a0b1-43bbbfc71f2d
DOI: 10.1101/826198

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Candidate methylation sites associated with endocrine therapy resistance in the TCGA ER+/HER2- breast cancer cohortDOI 10.1101/826198Read

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancerSemantic proximity Read

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesSemantic proximity Read

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.Semantic proximity Read

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancerSemantic proximity Read

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targetsSemantic proximity Read

ENDORSE: a prognostic model for endocrine therapy response in advanced estrogen-receptor positive breast cancersSemantic proximity Read

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancersSemantic proximity Read

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read